Yuanjing Hu

Dr. Yuanjing Hu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
WGWendi Guo
Wendi Guo
RRRunling Ren
Runling Ren
YHYuanjing Hu
Yuanjing Hu
YHYuanjing Hu
Yuanjing Hu
The survival outcomes of Stage IIIC1 in FIGO 2018 showed significant heterogeneity and it seems unreasonable to administer a uniform treatment regimen for Stage IIIC1 patients. This study aimed to assess the survival outcomes among patients with locally advanced cervical cancer based on various lymph node statuses, T-stage classifications, and treatment modalities. This is a population-based cohort study utilizing the Surveillance, Epidemiology, and End Results Program from 2004 to 2018. Propensity score-based inverse probability of treatment weighting was used to achieve covariate balance. Women with locally advanced cervical cancer on different lymph node statuses who underwent radical hysterectomy + pelvic lymphadenectomy + chemoradiotherapy, chemoradiotherapy, or radiotherapy alone were examined. Trends, patient characteristics, and survival outcomes were compared across different treatment regimens. Among 8777 patients analyzed, patients with early T-stage and married were identified as independent protective factors for cancer-specific survival regardless of lymph node status. The survival outcomes ranked in descending order as follows: T1N0>T2N0>T1N1 = T2N1>T3N0>T3N1. Therefore, the FIGO Stage IIIC1 was re-stratified into IIC (T1N1+T2N1) and IIIC1(T3N1). Patients who underwent radical hysterectomy combined with adjuvant therapy exhibited superior 5-year cancer-specific survival rates compared to those treated with chemoradiotherapy among IB3, IIA2, and IIC. The therapeutic efficacy of chemoradiotherapy surpassed that of radiotherapy alone in IIIA, IIIB, IIIC1(T3N1), and IVA patients. Restratification of Stage IIIC1 based on T-stage effectively discerns patients with divergent prognoses. Radical surgery + chemoradiotherapy is significantly associated with improved survival in early T-stage, regardless of lymph node status in locally advanced cervical cancer.

10 September 2023 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
XTXinyue Tang
Xinyue Tang
YHYuanjing Hu
Yuanjing Hu
YHYuanjing Hu
Yuanjing Hu
To investigate the influence of malignant peritoneal cytology (MPC) on the prognosis of early-stage patients with endometrial clear cell carcinoma(CCC) and serous carcinoma(SC), and the value of chemotherapy in their treatment. A retrospective observational cohort study was conducted by querying the National Cancer Institute's Surveillance, Epidemiology, and End Results Program from 2010 to 2019. Women with early-stage CCC and SC with available peritoneal cytology results were enrolled. Propensity score matching(PSM) and propensity score inverse probability of treatment weighting (IPTW) was used to balance the measured covariates in each sub-cohort. A total of 3,616 eligible patients were included, and 368 patients had MPC (10.2%). Women with MPC were more likely to receive postoperative chemotherapy (OR 2.033; 95%CI 1.589-2.602). In PSM model, MPC had worse overall survival(OS) and cancer-specific survival (CSS) (All,p < 0.001). The 5-year OS rates were 56.5% for women with MPC and 74.4% for those with negative peritoneal cytology, and the 5-year CSS rates were 60.8% versus 80.0%(All, p < 0.0001). In the subgroup analyses, MPC was associated with decreased OS and CSS in serous, clear cell histology group, and stage IA cases(All,p < 0.001), but not for stage IB or stage II disease. In multivariate analysis, chemotherapy improved the prognosis of patients with MPC(OS:p = 0.005; CSS:p = 0.010). Additionally, in stage IA subgroup, chemotherapy improved survival outcomes in patients with MPC(OS:P = 0.025; CSS:P = 0.038), in NPC patients, however, chemotherapy was a good prognostic factor for OS (P = 0.001) but not for CSS(P = 0.300). MPC was a prognostic factor for decreased survival in early-stage endometrial CCC and SC, and those with MPC could further benefit from chemotherapy.

23 June 2026 in Cell Proliferation
Verified
Journal Article
Open access
WGWendi Guo
Wendi Guo
TLTianxiang Liu
Tianxiang Liu
RRRunling Ren
Runling Ren
YHYuanjing Hu
Yuanjing Hu
WZWenwen Zhang
Wenwen Zhang
YHYuanjing Hu
Yuanjing Hu
Lymphovascular space invasion (LVSI) is a critical factor linked to metastasis and poor outcomes in endometrioid endometrial carcinoma (EEC), yet its multicellular mechanisms remain unclear. Using single‐cell RNA sequencing of 3 LVSI‐present (LVSI+) EECs, 2 LVSI‐absent (LVSI−) EECs, and 2 normal endometrial samples, we delineated the cellular ecosystems underlying LVSI. LVSI+ EECs exhibited marked epithelial reprogramming, transitioning from differentiated ciliated epithelium to hyperproliferative and metabolically remodelled phenotypes, and contained TC4, a metastatic epithelial subset characterized by hypoxia, partial epithelial–mesenchymal transition, immunosuppression, and progesterone resistance. We also identified nine key genes in malignant epithelial cells associated with LVSI prognosis. The tumour microenvironment in LVSI+ EECs shifted from an inflammatory state dominated by epithelial cells to a collaborative network involving stromal and immune cells. This network was enriched in immunosuppressive ZNF683 + SOX4 + CD8+ T cells, Cycling_T cells, SPP1 + MMP9 + Mac, WNT5A_mCAF, Tip endothelial cells, and lymphatic endothelial cells. WNT5A_mCAF and SPP1 + MMP9 + Mac synergistically remodelled the extracellular matrix, promoted lymphangiogenesis and angiogenesis, and, together with endothelial cells, suppressed T‐cell activity via LGALS9–HAVCR2/CD44 inhibitory signalling, thereby establishing a niche conducive to vascular invasion. Using spatial multiplex immunofluorescence, we confirmed hypoxic tumour epithelial cells at the invasive front coexisting with an immunosuppressive microenvironment, and revealed spatial colocalization of PD‐L1+ tumour cells, PD‐L1+ macrophages, and PD‐1+ T cells within LVSI thrombi. Our comprehensive study provides deeper insights into LVSI as an actively coordinated multicellular process, potentially improving LVSI risk prediction, supporting treatment decision‐making, and informing new therapies targeting the tumour microenvironment.

18 January 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
WGWendi Guo
Wendi Guo
RRRunling Ren
Runling Ren
YHYuanjing Hu
Yuanjing Hu
YHYuanjing Hu
Yuanjing Hu

24 October 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YHYuanjing Hu
Yuanjing Hu
ZYZelin Yu
Zelin Yu
XLXiao Li
Xiao Li
YGYuan Gao
Yuan Gao
YHYuanjing Hu
Yuanjing Hu
The 2023 (1st Edition) NCCN guideline changed the negative margin criteria for cervical conization from ≥ 3 mm to ≥ 1 mm. To explore the clinical safety of this up-dation in the real world, we performed a retrospective study to validate the rationality of the negative margin criteria for conization in patients with early-stage cervical cancer. We retrospectively collected the clinical and pathological data of 986 patients with early-stage cervical cancer from June 2011 to June 2023. All of the patients underwent conization and secondary (radical) hysterectomy at Tianjin Central Hospital of Gynecology Obstetrics. Patients were divided into four groups based on the status of the conization margins: margin < 1 mm (n = 132), margin < 3 mm (n = 147), margin involved (n = 443), and margin not involved (n = 264). The safety of the negative margin criteria for conization (< 1 mm) was evaluated by comparing the residual disease rates in different groups after secondary (radical) hysterectomy. Additionally, univariate and logistic multivariate analyses were conducted to identify the risk factors for residual disease after hysterectomy. A total of 986 patients with cervical cancer at stages IA1-IB1 were included. Among these patients, 382 had residual diseases (HSIL or higher) after hysterectomy, resulting in a residual disease rate of approximately 38.7%. Patients were categorized based on margin status (< 1 mm, <3 mm, margin involved, and, margin not involved). There were statistically significant differences in residual disease rates among the four groups (P < 0.05). There is no significant difference in residual disease rates between patients with the margin < 1 mm and margin < 3 mm, nor between these two groups and the margin not involved group. However, the residual disease rates in cases with margins < 1 mm and margins < 3 mm were significantly lower compared to those with margin involvement. Univariate analysis indicated that multiple factors, including age, were associated with residual disease. However, multivariate analysis revealed that age (P = 0.002, OR = 1.041, 95% CI 1.014–1.069), involvement of the margin by the lesion (P < 0.001, OR = 7.655, 95% CI 4.745–12.349), and cervical biopsy pathology showing cancer (P = 0.020, OR = 1.571, 95% CI 1.074–2.298) were independent risk factors for residual disease after hysterectomy in early-stage cervical cancer patients. Our findings suggest that a ≥ 1 mm negative margin criterion appears to be a safe threshold for early-stage cervical cancer, yet prospective validation is still required.